Usted buscó: palmitate (Maltés - Inglés)

- sucrose palmitate
- sucrose palmitate

- fiħ sucrose palmitate:
- contains sucrose palmitate:

l-ascorbyl 6-palmitate
l-ascorbyl 6-palmitate

10. 0 mg ta ’ sucrose palmitate, li
10.0 mg of sucrose palmitate,

fih ukoll e951, sucrose palmitate, potassium.
also contains e95, sucrose palmitate, potassium.

paliperidone palmitate u paliperidone ma kinux ġenotossiċi.
paliperidone palmitate and paliperidone were not genotoxic.

paliperidone palmitate u paliperidone ma kinux tossiċi għall-ġeni.
paliperidone palmitate and paliperidone were not genotoxic.

ascorbyl palmitate, butylated hydroxytoluene (e321) u lactose monohydrate.
palmitate, butylated hydroxytoluene (e321) and lactose monohydrate.

kull siringa mimlija għal-lest fiha paliperidone palmitate ekwivalenti għal 100 mg paliperidone.
each pre-filled syringe contains paliperidone palmitate equivalent to 100 mg paliperidone.

paliperidone palmitate huwa l-mediċina mhux attiva palmitate ester ta’ paliperidone.
paliperidone palmitate is the palmitate ester prodrug of paliperidone.

kull siringa mimlija għal-lest fiha 273 mg paliperidone palmitate ekwivalenti għal 175 mg paliperidone.
each pre-filled syringe contains 273 mg paliperidone palmitate equivalent to 175 mg paliperidone.

kull siringa mimlija għal-lest fiha 117 mg ta’ paliperidone palmitate ekwivalenti għal 75 mg paliperidone.
each pre-filled syringe contains 117 mg paliperidone palmitate equivalent to 75 mg paliperidone.

kull siringa mimlija għal-lest ta’ xeplion 100 mg fiha 156 mg ta’ paliperidone palmitate.
each xeplion 100 mg pre-filled syringe contains 156 mg paliperidone palmitate.

ibda paliperidone palmitate ta’ kull xahar li jista’ jiġi injettat 3 xhur wara bid-doża li ġejja
initiate 1-monthly paliperidone palmitate injectable 3 months later at the following dose

il-possibbiltà li paliperidone palmitate injettat fil-muskoli jikkawża kanċer ġiet evalwata fil-firien.
the carcinogenic potential of intramuscularly injected paliperidone palmitate was assessed in rats.

dożi ta’ paliperidone palmitate ta’ kull xahar li jista’ jiġi injettat għal pazjenti li qed jibdlu minn trevicta
doses of 1-monthly paliperidone palmitate injectable for patients switching from trevicta

injezzjoni ta’ paliperidone palmitate ta’ kull 3 xhur li taħdem fit-tul versus formulazzjonijiet oħra ta’ paliperidone
long-acting 3-monthly paliperidone palmitate injection versus other paliperidone formulations

il-bijodisponibbilità assoluta ta’ paliperidone palmitate wara l-għoti ta’ xeplion hija ta’ 100%.
the absolute bioavailability of paliperidone palmitate following xeplion administration is 100%.

fih ukoll aspartame (e951) bħala sustanza li tagħti togħma ħelwa, sucrose palmitate, potassium, benna naturali u artifiċjali u kostitwenti oħra.
also contains sweetener aspartame (e951), sucrose palmitate, potassium, natural and artificial flavourings and other constituents.

p2 = l-ogħla parti ta' palmitate tal-metil miksuba mill-kromatogramma tal-bqija tal-frazzjoni
p2 = peak area of methyl palmitate obtained from the chromatogram of the remaining fraction